Zobrazeno 1 - 10
of 22
pro vyhledávání: '"BUZDAR, A"'
Autor:
Aman U. Buzdar, Funda Meric-Bernstam, Ana M. Gonzalez-Angulo, Gabriel N. Hortobagyi, Soley Bayraktar, Xiudong Lei, Aysegul A. Sahin, Henry Mark Kuerer, Vicente Valero, Amal Melhem-Bertrandt
Publikováno v:
Cancer. 118:2385-2393
Background To evaluate the pathologic complete response (pCR) rates and relapse-free survival (RFS) and overall survival (OS) of patients receiving neoadjuvant systemic therapy (NST) with trastuzumab in combination with an anthracycline- or a non-ant
Autor:
Julia L. Oh, George H. Perkins, Aman U. Buzdar, Eric A. Strom, Welela Tereffe, Thomas A. Buchholz, Pamela K. Allen, Kelly K. Hunt, Reina Guzman, Jeffrey M. Albert, Karen E. Hoffman, Wendy A. Woodward
Publikováno v:
Breast Cancer Research and Treatment. 128:421-427
A previous randomized trial (CALGB 9344/Intergroup 0148) compared four cycles of adjuvant doxorubicin/cyclophosphamide (AC) to four cycles of AC plus four cycles of paclitaxel (AC + T) and demonstrated that the addition of paclitaxel improved locoreg
Autor:
Vicente Valero, Peter F. Thall, Andrew D. Seidman, Kristine Broglio, Susan G. Arbuck, Frankie A. Holmes, Aman U. Buzdar, Anthony W. Tolcher, Gabriel N. Hortobagyi, Stacy L. Moulder
Publikováno v:
Cancer. 116:814-821
Purpose To compare efficacy and toxicity profiles of paclitaxel using 3-hour versus 96-hour infusion schedules.
Autor:
Aman U. Buzdar
Publikováno v:
Cancer. 110:2394-2407
Despite proven benefits of neoadjuvant chemotherapy in patients with locally advanced, invasive breast cancer, no regimen is recommended as the treatment of choice. Neoadjuvant chemotherapy regimens encompass single-agent and combination therapy and
Autor:
Eleftherios P. Mamounas, Michael Baum, Mitchell Dowsett, Anthony Howell, Generosa Grana, Robert W. Carlson, Richard M. Elledge, William J. Gradishar, D. Craig Allred, Aman U. Buzdar
Publikováno v:
The Breast Journal. 9:213-222
This article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer
Autor:
Daniel J. Booser, Stephen E. Jones, Eric P. Winer, Allen S. Melemed, Aman U. Buzdar, Patrick Peterson, John E. Pippen, Joyce A. O'Shaughnessy, Clifford A. Hudis, Pamela N. Munster
Publikováno v:
Journal of Clinical Oncology. 21:1007-1014
Purpose: To select a daily dose of arzoxifene ( LY353381 ), a selective estrogen receptor modulator, for use in future studies in women with locally advanced or metastatic breast cancer who are either potentially tamoxifen sensitive (TS) or tamoxifen
Autor:
Lan Ni, Richard Theriault, Maureen A. Major, Kapil Dhingra, Andrew D. Seidman, Pamela N. Munster, Larry Norton, Clifford A. Hudis, Daniel J. Booser, Aman U. Buzdar, Allen S. Melemed, Nathan H. Enas
Publikováno v:
Memorial Sloan Kettering Cancer Center
PURPOSE: We conducted this phase I trial to determine the safety and toxicity profile of LY353381.HCl—a novel, potent, third-generation selective estrogen receptor modulator (SERM)—because this benzothiophene derivative demonstrated an SERM profi
Autor:
Edgardo Rivera, Marsha D. McNeese, Naoto T. Ueno, Gabriel N. Hortobagyi, Aman U. Buzdar, Carol B. Stelling, Kelly K. Hunt, Barbara J. Wasaff, Nuhad K. Ibrahim, Eric A. Strom, Vicente Valero, Nour Sneige, Daniel J. Booser, Eva Singletary, Terry K. Smith, Massimo Cristofanilli, James L. Murray
Publikováno v:
Cancer. 92:1775-1782
BACKGROUND Inflammatory breast carcinoma (IBC) is a rare but aggressive form of breast carcinoma. Anthracycline-based regimens represent the standard of treatment for IBC. Reports of significant clinical activity of paclitaxel in metastatic breast ca
Publikováno v:
Breast Cancer Research and Treatment. 58:157-162
Background. This paper reports on the clinical relevance of durable static disease (SD) (≥24 weeks) in breast cancer patients treated with the aromatase inhibitor anastrozole. Patients and methods. All patients were part of two prospective, randomi
Publikováno v:
The Breast. 5:312-317
First-line chemotherapy for matastatic breast cancer extends median survival by 9–12 months. A small fraction of patients achieve long-term remission with standard chemotherapy. With second-line chemotherapies, there is an objective response of 25